Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y · Cell Metabolism

Twelve months of oral NMN at 100 or 300 mg/kg/day dose-dependently suppressed age-related weight gain and improved insulin sensitivity, tear production and bone mineral density, raised food intake, oxygen consumption and energy expenditure, and preserved rod and cone photoreceptor function, with no toxicity or excess mortality. Glucose tolerance did not differ from control at any timepoint. The plasma lipid result was an interaction over time on free fatty acids rather than a difference between groups at any single one. Physical activity split by dose: 100 mg/kg raised dark-period ambulation while 300 mg/kg slightly lowered it and reduced rearing throughout the dark period. Lifespan was not an endpoint.

Population

Wild-type C57BL/6N mice on regular chow through normal ageing

Intervention

Oral NMN in drinking water for 12 months

Comparator

Untreated littermates

Limitations

Mouse; no joint or cartilage endpoint, though bone mineral density was measured. The doses scale well above typical human supplementation. Run as a sponsored research project of an NMN manufacturer, which generated and supplied the compound and employs two of the co-authors.